Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.
SIRP-alpha is a receptor expressed by myeloid lineage cells such as Dendritic Cells (DCs), tumor-associated macrophages (TAMs) and Myeloid-Derived Suppressor Cells (MDSCs). In targeting SIRP- alpha, OSE-172 prevents the ligand CD47 from binding to and triggering the cellular inhibitory effects of SIRP-alpha. OSE-172 has the potential to enhance anti-tumor immunity by improving T cell activity through enhancement of DC antigen presentation functionality, potentiating the phagocytic and inflammatory properties of macrophages in the tumor microenvironment and enabling differentiation of MDSCs to an effector state.
“This partnership with Boehringer Ingelheim is a real recognition of the value of our innovative approach to treating cancer and will create an exciting new alliance to fuel the phase 1 development of OSE-172,” said Dr. Dominique Costantini, CEO of OSE Immunotherapeutics. “Boehringer Ingelheim’s expertise and insights will be invaluable as we step up the clinical development and work to commercialize this new treatment paradigm.”
“We are excited to partner with OSE Immunotherapeutics to develop this promising, novel cancer immunotherapy,” said Jonathon Sedgwick, Ph.D., Global Head Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “A key area of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example. We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”
Boehringer Ingelheim has acquired the global rights to develop, register and commercialize OSE-172, a monoclonal antibody targeting SIRP-alpha which is expressed in myeloid lineage cells, as part of their continued commitment to research and innovation in immuno-oncology. Under the terms of the agreement, OSE Immunotherapeutics will receive a €15 million upfront payment from Boehringer Ingelheim, and potential additional short-term milestones of up to €15 million upon initiation of a phase 1 clinical study. OSE Immunotherapeutics stands to receive more than €1.1 billion upon reaching pre-specified development, commercialization and sales milestones, plus royalties on worldwide net sales.
Please click on the link for ‘Notes to Editors’: http://www.boehringer-ingelheim.com/New-Partnership-to-develop-novel-checkpoint-inhibitor
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
Alexis Peyroles, COO
P: +33 611 511 977
French Media: FP2COM
P: +33 607 768 283
Linda Dyson, MPH
U.S. Media: LifeSci Public Relations
P: +1 973.986.5973
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
New Industry Research Shows Augmented Reality Adopters Have Best-in-Class Performance Related to Factory Operations, Service, and Training18.10.2018 13:00 | Tiedote
PTC (NASDAQ: PTC) today announced from Augmented World Expo (AWE) Europe 2018 the availability of new research in conjunction with Aberdeen Group titled, “How the Best-in-Class Use Augmented Reality for Superior Service Management.” The comprehensive research study and corresponding report identifies significant financial improvements realized by industrial companies embracing augmented reality (AR), and provides best practices for unlocking the potential of the technology across various environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005051/en/ PTC announced exclusive data from Aberdeen Group shows that organizations using augmented reality have experienced significant year-over-year business growth and have improved their bottom lines dramatically. (Graphic: Business Wire). In addition to the report published today, PTC announced exclusive data from Aberdeen that shows that organizations using AR have ex
PotNetwork Holdings, Inc. Concludes Record Breaking 3rd Quarter with Revenues Exceeding $6.1 Million18.10.2018 13:00 | Tiedote
PotNetwork Holdings, Inc. (OTC Pink: POTN ) today announced third quarter revenues totaling $6.1 Million representing a 37% increase over the same period last year. The Company committed to increasing marketing during the last year resulting in the increase of year over year revenue. The marketing budget increased by more than 200% during that time. Diamond CBD distributes premium quality products and has established a successful, continually broadening distribution footprint. Diamond CBD’s products are taking advantage of the popularity of hemp-derived CBD. Diamond’s hemp-derived CBD products do not contain any THC and are tested for purity. Driven by the continually growing results of its wholly-owned subsidiary, Diamond CBD, Inc., PotNetwork Holdings, Inc. has recently filed its Form 10 registration statement with the U.S. Securities and Exchange Commission that includes the Company’s audited financial statements. Additionally, PotNetwork Holdings, Inc. intends to seek listing on th
Cigalah Medpharm Announces the Launch in Saudi Arabia and United Arab Emirates of Nexodyn® AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma Company APR18.10.2018 12:30 | Tiedote
Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based cleanser for acute and chronic wound management, is now starting to be available in Saudi Arabia and United Arab Emirates (UAE), promoted and commercialized by the leading pharmaceutical company Cigalah Medpharm, part of Cigalah Group, following an exclusive partnership with the Swiss Pharma company APR Applied Pharma Research (“APR”). The current size of wound care market in Saudi Arabia and United Arab Emirates accounts for almost 70 million USD and it’s expected to keep growing in the next years because of the aging of the population and the increasing prevalence of chronic wounds, which represent roughly the 70% of the total market. As confirmed by market research, strong is the need from Healthcare Professionals (HCP) of new treatment options to ensure a faster and effective wound healing. The innovative wound cleanser, Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, offers to HCPs and caregivers a n
New Open Applications Advance Comprehensive Modeling Environment for Multidiscipline Collaboration18.10.2018 11:58 | Tiedote
The Year in Infrastructure 2018 Conference – Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today launched OpenSite Designer, a built-for-purpose application for the design and construction of civil site projects. It also launched OpenBuildings, bringing together its AECOsim building design and Speedikon factory and industrial design applications; and announced the availability of OpenBuildings Station Designer, a specialized application for designing rail and metro stations. At the same time, Bentley announced the availability of OpenBridge Designer, which combines Bentley’s bridge modeling, analysis and design capabilities into one comprehensive package, and OpenFlows FLOOD, a flood analysis and early warning system. In addition, in pursuit of its ‘industrialization’ strategy, Bentley announced it has rebranded under its Open portfolio several of its applications
Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc18.10.2018 10:19 | Tiedote
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received unconditional clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”). The receipt of antitrust clearance in Japan is another significant step towards closing the transaction. In addition to Japan, the Acquisition has now received unconditional clearances from regulatory authorities in multiple key jurisdictions, including the United States, China and Brazil, among others. “We are very pleased to have received unconditional clearance from the Japan Fair Trade Commission for our proposed acquisition of Shire,” said Christophe Weber, President and Chief Executive Officer of Takeda. “Takeda is proud of its Japanese heritage, and we are look
FedEx Expanding Freight Forwarding Capabilities with Acquisition of Manton18.10.2018 09:00 | Tiedote
FedEx Corp. (NYSE:FDX) announced today that it has agreed to acquire Manton Air-Sea Pty Ltd, a leading provider of logistics services, including freight forwarding and customs brokerage solutions. Manton’s capabilities complement and expand the FedEx portfolio of offerings essential to the rapidly growing global commerce landscape. The acquisition is expected to close later this year and is subject to customary closing conditions. With operations across Australia, Manton connects customers to global markets through regional gateways and relationships with multiple air carriers. With specific expertise in the healthcare and automotive markets, Manton is a proven leader in air and ocean freight forwarding solutions, as well as customs brokerage. Headquartered in Sydney, Australia, Manton will operate as a subsidiary of the FedEx Trade Networks operating company. “Adding Manton’s capabilities to FedEx Trade Networks and the broader FedEx portfolio will open up opportunities for us to cont
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme